ArticleBMC cardiovascular disorders2026
Clinical significance of lncRNA GAS5 in deep vein thrombosis and its mechanism of action on vascular endothelial damage.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe current research aims to clarify the clinical significance and molecular function of long-non-coding RNA growth arrest-specific 5 (GAS5) in deep vein thrombosis (DVT).
methods92 DVT patients and 86 controls were included in this study. Real-time quantitative reverse transcription PCR (RT-qPCR) was performed to measure GAS5, microRNA (miR)-134-5p, and forkhead box protein 3 (FOXP3) levels. Receiver operating characteristic (ROC) curves evaluated the diagnostic significance of GAS5 in DVT. Kaplan-Meier and Cox regression analyses assessed the prognostic significance of post-thrombotic syndrome (PTS). An in vitro model using CoCl
resultsGAS5 and FOXP3 were downregulated in DVT patients' serum and CoCl
conclusionGAS5 levels are decreased in DVT patients, serving as a diagnostic and prognostic biomarker. Elevated GAS5 targets miR-134-5p/FOXP3 axis to alleviate endothelial dysfunction and inflammation, thereby reducing thrombosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.